Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyVisceral SurgeryDiseaseFallopian Tube CarcinomaOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupICD10C56C57.0C78.6MeSHCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsSequenceChemotherapyChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances5Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseintraoperativTherapy intentionpalliativeRisksDyspneaElectrolyte DisturbanceEmetogenicity (MASCC/ESMO)InfectionsPainThromboembolic Event only studiesPublicationAuthorvan Driel WDiseaseNeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2OriginDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamProtocols in Revision 1 protocol foundProtocols under revision.HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.1)
